NCT06812585View on ClinicalTrials.gov

The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

January 30, 2025

Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
DRUG

Metformin (Cidophage®)

Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.

OTHER

Usual Care

Active Comparator: Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®) Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)

Trial Locations (1)

1053

Nasser Institute for Research and Treatment, Cairo

All Listed Sponsors
lead

German University in Cairo

OTHER